The global market for Parkinson's Disease Treatment is estimated at US$5.7 Billion in 2023 and is projected to reach US$8 Billion by 2030, growing at a CAGR of 4.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Parkinson's Disease Treatment Market]( "Parkinson's Disease Treatment Market")
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Levodopa / Carbidopa Drug Class segment, which is expected to reach US$2.9 Billion by 2030 with a CAGR of a 6.1%. The Dopamine Receptor Agonists Drug Class segment is also set to grow at 4.4% CAGR over the next 7 years.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2023, and China, forecasted to grow at an impressive 7.6% CAGR to reach $1.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Parkinson's Disease Treatment Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Parkinson's Disease Treatment Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Parkinson's Disease Treatment Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie, Acadia, Boehringer Ingelheim, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 42 Featured):
- AbbVie
- Acadia
- Boehringer Ingelheim
- Dr. Reddy’s
- GSK
- Impax
- Lundbeck
- Merck
- Novartis
- Sun Pharma
- Teva
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Wockhardt
MarketGlass Platform
Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Parkinson's Disease Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 2: World Historic Review for Parkinson's Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 3: World 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Levodopa / Carbidopa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 5: World Historic Review for Levodopa / Carbidopa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 6: World 16-Year Perspective for Levodopa / Carbidopa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Dopamine Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 8: World Historic Review for Dopamine Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 9: World 16-Year Perspective for Dopamine Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 10: World Recent Past, Current & Future Analysis for MAO-Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 11: World Historic Review for MAO-Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 12: World 16-Year Perspective for MAO-Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 13: World Recent Past, Current & Future Analysis for COMT-inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 14: World Historic Review for COMT-inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 15: World 16-Year Perspective for COMT-inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 17: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 18: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 20: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 21: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 23: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 24: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 26: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 27: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 28: World Parkinson's Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 30: USA Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 31: USA 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 33: USA Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 34: USA 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 36: Canada Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 37: Canada 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 39: Canada Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 40: Canada 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
JAPAN
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 42: Japan Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 43: Japan 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 45: Japan Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 46: Japan 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
CHINA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 47: China Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 48: China Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 49: China 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 51: China Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 52: China 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
EUROPE
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 54: Europe Historic Review for Parkinson's Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 55: Europe 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 57: Europe Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 58: Europe 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 60: Europe Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 61: Europe 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
FRANCE
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 62: France Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 63: France Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 64: France 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 66: France Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 67: France 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
GERMANY
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 69: Germany Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 70: Germany 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 72: Germany Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 73: Germany 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 75: Italy Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 76: Italy 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 78: Italy Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 79: Italy 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 81: UK Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 82: UK 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 84: UK Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 85: UK 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
SPAIN
- Table 86: Spain Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 87: Spain Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 88: Spain 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 89: Spain Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 90: Spain Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 91: Spain 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
RUSSIA
- Table 92: Russia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 93: Russia Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 94: Russia 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 95: Russia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 96: Russia Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 97: Russia 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 100: Rest of Europe 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 101: Rest of Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 102: Rest of Europe Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 103: Rest of Europe 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Parkinson's Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 109: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
- Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 111: Asia-Pacific Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 112: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
AUSTRALIA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
LATIN AMERICA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
MIDDLE EAST
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
AFRICA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Acadia
- Boehringer Ingelheim
- Dr. Reddy’s
- GSK
- Impax
- Lundbeck
- Merck
- Novartis
- Sun Pharma
- Teva
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Wockhardt
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 93 |
| Published | November 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 5.7 Billion |
| Forecasted Market Value ( USD | $ 8 Billion |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
